Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis

Fedja A. Rochling, Whitney F. Jones, Kurt Chau, Louise DuCharme, Larry T. Mimms, Bonnie Moore, James Scheffel, Jennifer A Cuthbert, Dwain L Thiele

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Patients presenting with clinical and laboratory features consistent with a diagnosis of acute non-A, non-B hepatitis were evaluated for evidence of hepatitis C or hepatitis E infection and for evidence of severe or prolonged disease. Antibody to hepatitis C virus (anti-HCV) was detected in 75 of 108 (69%) patients, antibody to hepatitis E virus (anti-HEV) in three patients (3%), and neither antibody in 31 (29%) patients. One patient had both anti-HCV and anti-HEV. HCV RNA was not detected in sera from any of 20 patients with seronegative (non-ABCDE) hepatitis, but in all 10 patients with anti-HCV who were tested by polymerase chain reaction (PCR). Compared with patients with acute hepatitis C, those with non-ABCDE hepatitis had a lower incidence of parenteral risk factors (6% vs. 70%; P < .001), higher peak serum bilirubin levels (45% vs. 5% with peak levels >15 mg/dL; P < .001), more prolonged jaundice (25% vs. 0% with peak bilirubin >5 weeks after onset; P < .01), more severe prothrombin time abnormalities (26% vs. 0% with >3 second prolongation; P < .001), more severe hypoalbuminemia (39% vs. 9% with albumin <3 g/dL; P < .01), and more frequent major clinical complications (13% vs. 0% with encephalopathy; P < .01; 10% vs. 0% with death or transplant; P = .024). Patients with acute non-ABCDE hepatitis were less likely to develop chronic hepatitis than those with acute hepatitis C (23% vs. 68%; P < .05). Thus, patients with acute non-ABCDE hepatitis are epidemiologically distinct from those with acute hepatitis C and have a significantly more severe acute illness.

Original languageEnglish (US)
Pages (from-to)478-483
Number of pages6
JournalHepatology
Volume25
Issue number2
StatePublished - Feb 1997

Fingerprint

Hepatitis
Hepatitis C
Hepatitis C Antibodies
Hepatitis E virus
Antibodies
Hepatitis E
Hypoalbuminemia
Brain Diseases
Chronic Hepatitis
Albumins
RNA
Transplants
Polymerase Chain Reaction
Incidence
Infection
Serum

ASJC Scopus subject areas

  • Hepatology

Cite this

Rochling, F. A., Jones, W. F., Chau, K., DuCharme, L., Mimms, L. T., Moore, B., ... Thiele, D. L. (1997). Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis. Hepatology, 25(2), 478-483.

Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis. / Rochling, Fedja A.; Jones, Whitney F.; Chau, Kurt; DuCharme, Louise; Mimms, Larry T.; Moore, Bonnie; Scheffel, James; Cuthbert, Jennifer A; Thiele, Dwain L.

In: Hepatology, Vol. 25, No. 2, 02.1997, p. 478-483.

Research output: Contribution to journalArticle

Rochling, FA, Jones, WF, Chau, K, DuCharme, L, Mimms, LT, Moore, B, Scheffel, J, Cuthbert, JA & Thiele, DL 1997, 'Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis', Hepatology, vol. 25, no. 2, pp. 478-483.
Rochling FA, Jones WF, Chau K, DuCharme L, Mimms LT, Moore B et al. Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis. Hepatology. 1997 Feb;25(2):478-483.
Rochling, Fedja A. ; Jones, Whitney F. ; Chau, Kurt ; DuCharme, Louise ; Mimms, Larry T. ; Moore, Bonnie ; Scheffel, James ; Cuthbert, Jennifer A ; Thiele, Dwain L. / Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis. In: Hepatology. 1997 ; Vol. 25, No. 2. pp. 478-483.
@article{139670bccc2344eda1b16ebec80cfc1b,
title = "Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis",
abstract = "Patients presenting with clinical and laboratory features consistent with a diagnosis of acute non-A, non-B hepatitis were evaluated for evidence of hepatitis C or hepatitis E infection and for evidence of severe or prolonged disease. Antibody to hepatitis C virus (anti-HCV) was detected in 75 of 108 (69{\%}) patients, antibody to hepatitis E virus (anti-HEV) in three patients (3{\%}), and neither antibody in 31 (29{\%}) patients. One patient had both anti-HCV and anti-HEV. HCV RNA was not detected in sera from any of 20 patients with seronegative (non-ABCDE) hepatitis, but in all 10 patients with anti-HCV who were tested by polymerase chain reaction (PCR). Compared with patients with acute hepatitis C, those with non-ABCDE hepatitis had a lower incidence of parenteral risk factors (6{\%} vs. 70{\%}; P < .001), higher peak serum bilirubin levels (45{\%} vs. 5{\%} with peak levels >15 mg/dL; P < .001), more prolonged jaundice (25{\%} vs. 0{\%} with peak bilirubin >5 weeks after onset; P < .01), more severe prothrombin time abnormalities (26{\%} vs. 0{\%} with >3 second prolongation; P < .001), more severe hypoalbuminemia (39{\%} vs. 9{\%} with albumin <3 g/dL; P < .01), and more frequent major clinical complications (13{\%} vs. 0{\%} with encephalopathy; P < .01; 10{\%} vs. 0{\%} with death or transplant; P = .024). Patients with acute non-ABCDE hepatitis were less likely to develop chronic hepatitis than those with acute hepatitis C (23{\%} vs. 68{\%}; P < .05). Thus, patients with acute non-ABCDE hepatitis are epidemiologically distinct from those with acute hepatitis C and have a significantly more severe acute illness.",
author = "Rochling, {Fedja A.} and Jones, {Whitney F.} and Kurt Chau and Louise DuCharme and Mimms, {Larry T.} and Bonnie Moore and James Scheffel and Cuthbert, {Jennifer A} and Thiele, {Dwain L}",
year = "1997",
month = "2",
language = "English (US)",
volume = "25",
pages = "478--483",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis

AU - Rochling, Fedja A.

AU - Jones, Whitney F.

AU - Chau, Kurt

AU - DuCharme, Louise

AU - Mimms, Larry T.

AU - Moore, Bonnie

AU - Scheffel, James

AU - Cuthbert, Jennifer A

AU - Thiele, Dwain L

PY - 1997/2

Y1 - 1997/2

N2 - Patients presenting with clinical and laboratory features consistent with a diagnosis of acute non-A, non-B hepatitis were evaluated for evidence of hepatitis C or hepatitis E infection and for evidence of severe or prolonged disease. Antibody to hepatitis C virus (anti-HCV) was detected in 75 of 108 (69%) patients, antibody to hepatitis E virus (anti-HEV) in three patients (3%), and neither antibody in 31 (29%) patients. One patient had both anti-HCV and anti-HEV. HCV RNA was not detected in sera from any of 20 patients with seronegative (non-ABCDE) hepatitis, but in all 10 patients with anti-HCV who were tested by polymerase chain reaction (PCR). Compared with patients with acute hepatitis C, those with non-ABCDE hepatitis had a lower incidence of parenteral risk factors (6% vs. 70%; P < .001), higher peak serum bilirubin levels (45% vs. 5% with peak levels >15 mg/dL; P < .001), more prolonged jaundice (25% vs. 0% with peak bilirubin >5 weeks after onset; P < .01), more severe prothrombin time abnormalities (26% vs. 0% with >3 second prolongation; P < .001), more severe hypoalbuminemia (39% vs. 9% with albumin <3 g/dL; P < .01), and more frequent major clinical complications (13% vs. 0% with encephalopathy; P < .01; 10% vs. 0% with death or transplant; P = .024). Patients with acute non-ABCDE hepatitis were less likely to develop chronic hepatitis than those with acute hepatitis C (23% vs. 68%; P < .05). Thus, patients with acute non-ABCDE hepatitis are epidemiologically distinct from those with acute hepatitis C and have a significantly more severe acute illness.

AB - Patients presenting with clinical and laboratory features consistent with a diagnosis of acute non-A, non-B hepatitis were evaluated for evidence of hepatitis C or hepatitis E infection and for evidence of severe or prolonged disease. Antibody to hepatitis C virus (anti-HCV) was detected in 75 of 108 (69%) patients, antibody to hepatitis E virus (anti-HEV) in three patients (3%), and neither antibody in 31 (29%) patients. One patient had both anti-HCV and anti-HEV. HCV RNA was not detected in sera from any of 20 patients with seronegative (non-ABCDE) hepatitis, but in all 10 patients with anti-HCV who were tested by polymerase chain reaction (PCR). Compared with patients with acute hepatitis C, those with non-ABCDE hepatitis had a lower incidence of parenteral risk factors (6% vs. 70%; P < .001), higher peak serum bilirubin levels (45% vs. 5% with peak levels >15 mg/dL; P < .001), more prolonged jaundice (25% vs. 0% with peak bilirubin >5 weeks after onset; P < .01), more severe prothrombin time abnormalities (26% vs. 0% with >3 second prolongation; P < .001), more severe hypoalbuminemia (39% vs. 9% with albumin <3 g/dL; P < .01), and more frequent major clinical complications (13% vs. 0% with encephalopathy; P < .01; 10% vs. 0% with death or transplant; P = .024). Patients with acute non-ABCDE hepatitis were less likely to develop chronic hepatitis than those with acute hepatitis C (23% vs. 68%; P < .05). Thus, patients with acute non-ABCDE hepatitis are epidemiologically distinct from those with acute hepatitis C and have a significantly more severe acute illness.

UR - http://www.scopus.com/inward/record.url?scp=0031032715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031032715&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 478

EP - 483

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -